{
    "title": "Eli Lilly obesity drug data shines, shares rise",
    "url": "https://www.dailymail.co.uk/wires/reuters/article-10763023/Drugmaker-Eli-Lilly-profit-jumps-robust-demand-diabetes-drug.html",
    "date": "2022-04-28",
    "keywords": [
        "drug",
        "donanemab",
        "obesity",
        "approval",
        "fda",
        "share",
        "roy",
        "leroy",
        "latestage",
        "tirzepatide",
        "treatment",
        "loss",
        "analyst",
        "divan",
        "company",
        "quarter",
        "medicare",
        "coverage",
        "cms",
        "decision",
        "biogen",
        "daniel",
        "year",
        "thursday",
        "blockbuster",
        "goal",
        "weight",
        "trial",
        "drugmaker",
        "street",
        "type",
        "player",
        "market",
        "mohit",
        "bansal",
        "note",
        "peak",
        "vamil",
        "product",
        "submission",
        "food",
        "administration",
        "timeline",
        "application",
        "light",
        "proposal",
        "class",
        "april",
        "amp",
        "medicaid",
        "reimbursement",
        "process",
        "proof",
        "benefit",
        "removal",
        "brain",
        "decline",
        "incs",
        "study",
        "officer",
        "skovronsky",
        "timing",
        "review",
        "time",
        "side",
        "refinitiv",
        "forecast",
        "part",
        "leo",
        "bengaluru",
        "editing",
        "bill",
        "berkrot"
    ],
    "category": [
        "wires",
        "reuters"
    ]
}